Table 2.

Abnormal liver biochemistries during follow‐up among all patients with SARS‐CoV‐2 infection/COVID‐19 who had no HBV infection, who had current HBV infection, and who had past HBV infection

	No HBV (n = 4,927)	Current HBV Infection (n = 353)	Past HBV Infection (n = 359)	P
Acute liver injury	58 (1.2)	8 (2.3)	11 (3.1)	0.005
Peak ALT
< ULN	2,533 (51.4)	166 (47.0)	165 (46.0)	0.001
≥1 × to <2 × ULN	1,245 (25.3)	105 (29.7)	88 (24.5)
≥2 × to <5 × ULN	909 (18.4)	69 (19.5)	79 (22.0)
≥5 × to <10 × ULN	194 (3.9)	7 (2.0)	16 (4.5)
≥10 × ULN	46 (0.9)	6 (1.7)	11 (3.1)
Peak ALP
< ULN	4,378 (88.9)	319 (90.4)	298 (83.0)	0.003
≥1 × to <2 × ULN	485 (9.8)	30 (8.5)	47 (13.1)
≥2 × to <5 × ULN	58 (1.2)	4 (1.1)	14 (3.9)
≥5 × ULN	6 (0.1)	0 (0)	0 (0)
Peak total bilirubin
< ULN	3,804 (77.2)	276 (78.2)	249 (69.4)	0.001
≥1 × to <2 × ULN	953 (19.3)	60 (17.0)	85 (23.7)
≥2 × to <5 × ULN	151 (3.1)	15 (4.2)	19 (5.3)
≥5 × to <10 × ULN	12 (0.2)	2 (0.6)	5 (1.4)
≥10 × ULN	7 (0.1)	0 (0)	1 (0.3)
Peak AST*	n = 1,574	n = 145	n = 168
<ULN	929 (59.0)	84 (57.9)	87 (51.8)	0.134
≥1 × to <2 × ULN	379 (24.1)	45 (31.0)	41 (24.4)
≥2 × to <5 × ULN	217 (13.8)	13 (9.0)	32 (19.0)
≥5 × to <10 × ULN	33 (2.1)	2 (1.4)	6 (3.6)
≥10 × ULN	16 (1.0)	1 (0.7)	2 (1.2)
Peak GGT*	n = 938	n = 88	n = 118
<ULN	349 (37.2)	44 (50.0)	48 (40.7)	0.055
≥1 × to <2 × ULN	239 (25.5)	28 (31.8)	32 (27.1)
≥2 × to <5 × ULN	222 (23.7)	11 (12.5)	27 (22.9)
≥5 × to <10 × ULN	87 (9.3)	4 (4.5)	6 (5.1)
≥10 × ULN	41 (4.4)	1 (1.1)	5 (4.2)

For peak liver function tests during follow‐up, patients were followed from the date of COVID‐19 diagnosis to the date of discharge, the last follow‐up date (January 20, 2021), or date of death, whichever came first.

Acute liver injury was defined as ALT and/or AST ≥ 2 × ULN, with total bilirubin ≥2 × ULN and/or international normalized ratio ≥1.7.

^*Percentages were based on nonmissing data.

Abbreviation: GGT, gamma‐glutamyl transferase.